Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04631718 · ClinicalTrials.gov registry record
MRI QSM Imaging for Iron Overload
A clinical trial, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- 63
- Enrollment target
NCT04631718: Completed study, sponsored by University of Wisconsin, Madison.
NCT04631718 is a clinical trial that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04631718 has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- 63 participants
- Enrollment target
Study Summary
The overall goal of this project is to develop and validate a novel technique for Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM) of the abdomen, for non-invasive assessment of liver iron deposition. In this work, study team will develop and optimize advanced data acquisition and image reconstruction methods to enable QSM of the abdomen. Further, investigators will determine the accuracy, repeatability, and reproducibility of abdominal QSM for iron quantification in patients with liver iron overload. Excessive accumulation of iron in various organs, including the liver, which affects both adult and pediatric populations, is toxic and requires treatment aimed at reducing body iron stores. Accurate assessment of liver iron concentration is critical for the detection and staging of iron overload as well as for longitudinal monitoring during treatment. In summary, this project will develop a novel MRI-based QSM technique designed for the abdomen and will validate it in pediatric and adult patients with liver iron overload. Upon successful validation, QSM will provide accurate, repeatable, and reproducible quantification of LIC based on a fundamental property of tissue.
Primary Outcome
Determine the accuracy of abdominal QSM to quantify liver iron concentration at 1.5T and 3T, in pediatric and adult patients with liver iron overload, using superconducting quantum interference device (SQUID)-based biomagnetic liver susceptometry (BLS) as the reference.
Interventions
- RADIATION Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2022-01-18 |
| Est. Completion | 2024-04-29 |
What the finished NCT04631718 record still lists
NCT04631718 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM) is the first listed.
NCT04631718 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04631718 about?
NCT04631718 is a clinical study titled "MRI QSM Imaging for Iron Overload". The overall goal of this project is to develop and validate a novel technique for Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM) of the abdomen, for non-invasive assessment of liver iron deposition. In this work, study team will develop and optimize advanced data ac...
What is the current status of trial NCT04631718?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2022-01-18. Estimated completion is 2024-04-29.
What interventions are being tested in trial NCT04631718?
The interventions under investigation include: Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM) (RADIATION).
Who is sponsoring clinical trial NCT04631718?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI